Compare · DFTX vs IMCC
DFTX vs IMCC
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and IM Cannabis Corp. (IMCC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and IMCC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.83B, about 5394.1x IMCC ($895,536).
- DFTX has been more active in the news (5 items in the past 4 weeks vs 2 for IMCC).
- DFTX has more recent analyst coverage (5 ratings vs 3 for IMCC).
- Company
- Definium Therapeutics Inc.
- IM Cannabis Corp.
- Price
- $44.25+0.35%
- $0.14+0.07%
- Market cap
- $4.83B
- $895,536
- 1M return
- -
- -46.31%
- 1Y return
- -
- -95.90%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 2
- Recent ratings
- 5
- 3
IMCC
IM Cannabis Corp.
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Latest DFTX
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,315,236 worth of shares (29,208 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,098,246 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Wiley Matthew T. sold $129,101 worth of shares (2,867 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,633 units (SEC Form 4) (withholding obligation)
Latest IMCC
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million
- SEC Form EFFECT filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Announces Form F-3 Resale Registration Statement Filing
- SEC Form F-3 filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing